Alvotech licenses durvalumab and emicizumab biosimilar candidates to Lotus in ~$150M deal
Alvotech has signed a licensing and commercialisation agreement with Lotus Pharmaceutical covering two early-stage biosimilar candidates: AVT34, a proposed biosimilar to durvalumab (Imfinzi), and AVT87, a proposed biosimilar to emicizumab (Hemlibra).
Under the deal, Lotus gains commercialisation rights across the United States and selected Asian markets. The agreement has a potential value to Alvotech of up to approximately USD 150 million in upfront and milestone payments, plus royalties on future sales.
The tie-up extends Alvotech's biosimilar pipeline into oncology (durvalumab, a PD-L1 checkpoint inhibitor) and haemophilia (emicizumab, a factor VIIIa-mimetic bispecific antibody), while giving Lotus a broader specialty-biologics portfolio in its core Asian and US territories.
Source: Alvotech, 21 August 2026.